Download Full-Text PDF

Int. J. Mol. Sci. 2013, 14, 17573-17583; doi:10.3390/ijms140917573
OPEN ACCESS
International Journal of
Molecular Sciences
ISSN 1422-0067
www.mdpi.com/journal/ijms
Review
Prevention of Carcinogenesis and Development of Gastric and
Colon Cancers by 2-Aminophenoxazine-3-one (Phx-3):
Direct and Indirect Anti-Cancer Activity of Phx-3
Akio Tomoda 1,*, Keisuke Miyazawa 1 and Takafumi Tabuchi 2
1
2
Department of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo 160-8402, Japan;
E-Mail: [email protected]
Fourth Department of Surgery, Tokyo Medical University, Ibaragi Medical Center, 3-20-1 Chuo,
Ami, Inashiki, Ibaraki 300-0395, Japan; E-Mail: [email protected]
* Author to whom correspondence should be addressed; E-Mail: [email protected];
Tel.: +81-3-3351-6141 (ext. 244); Fax: +81-3-3351-6466.
Received: 8 July 2013; in revised form: 20 August 2013 / Accepted: 21 August 2013 /
Published: 28 August 2013
Abstract: 2-Aminophenoxazine-3-one (Phx-3), an oxidative phenoxazine, exerts strong
anticancer effects on various cancer cell lines originating from different organs, in vitro.
This article reviews new aspects for the prevention of carcinogenesis and development of
gastric and colon cancers by Phx-3, based on the strong anticancer effects of Phx-3 on gastric
and colon cancer cell lines (direct anticancer effects of Phx-3 for preventing development
of cancer), the bacteriocidal effects of Phx-3 against Helicobacter pylori associated with
carcinogenesis of gastric cancer (indirect anticancer effects for preventing carcinogenesis of
gastric cancer), and the proapoptotic activity of Phx-3 against human neutrophils involved in
the incidence of ulcerative colitis associated with a high colon cancer risk (indirect
anticancer effects for preventing carcinogenesis of colon cancer).
Keywords: Phx-3; gastric and colon cancers; apoptosis; neutrophils
1. Introduction
2-Aminophenoxazine-3-one (Phx-3) (Figure 1) was first reported as the antibiotics for streptomyces
discovered in soil in Kunitachi, Tokyo, Japan, in 1959 [1]. However, no further characterization of its
Int. J. Mol. Sci. 2013, 14
17574
bioactivity was carried out, possibly due to its weaker (and questionable) antibiotic effects against
various microbes except for Mycobacterium tuberculosis, and therefore, it was named questiomycin.
Tomoda and colleagues found in 1986 [2] that Phx-3 can be produced during the reaction of human
erythrocytes or hemoglobin with o-aminophenol, and later demonstrated that it does exert strong
anticancer effects both on various cancer cell lines [3–8] and cancer cell-transplanted mice in vivo [9,10],
as well as antimicrobial effects against Helicobacter pylori [11], Chlamydia pneumoniae [12], some
mycobacterial species [13], and herpes viruses [14]. Their studies demonstrated that Phx-3 causes
apoptotic cell death in the gastric and colon cancer cell line by decreasing intracellular pH, dysregulating
the function of mitochondria, and activating the caspase signaling [8,15–17]. Phx-3 also efficiently
suppresses the activity of Akt, which is responsible for the cell survival of cancer cells [7]. These results
indicate that Phx-3 has the potential to promote apoptosis of cancer cells, and therefore, may be applied
to treat such cancers as gastric cancer and colon cancer, which are refractory to chemotherapy. This
article describes the anticancer activity of Phx-3 against gastric and colon cancer cells in terms of
preventing the development of gastric and colon cancers (direct effects of Phx-3).
Figure 1. Chemical structure of Phx-3.
Recent research indicates that inflammation is a critical component of tumor development [18–20],
and that neutrophils, which play an important role in the inflammatory reactions in the body, are
potentially involved in the carcinogenesis, metastasis and angiogenesis of cancers [21]. In 1992,
Tabuchi et al. [22] found that tumor size significantly reduced when neutrophil (=granulocyte) was
deleted by extracorporeal circulation after being transplanted with VX2 carcinoma cells, a rabbit
papilloma cell line. Later, they demonstrated that neutrophils play a critical role in the development of
colon cancer. Namely, using granulocyte apheresis to remove these cells from the blood of
patients with colon cancer extensively reduced the size of the cancer, and they proposed that the
granulocytes/lymphocytes (G/L) ratio might be pivotal to the development of colon cancer in the
body [23,24]. This view has been extensively supported by reports that the increased number of
neutrophils in patients with colon cancer is evident [25] and that the G/L ratio in the peripheral blood is
significantly higher in the advanced stages of colon cancer [26,27]. In addition, neutrophils that produce
a large amount of active oxygen during inflammation are involved in ulcerative colitis and causative of
the carcinogenesis of colon cancer [28,29]. Therefore, suppression of the activity of neutrophils may
lead to preventing ulcerative colitis, and finally to preventing the carcinogenesis of colon cancer.
Recently, Tabuchi et al. [30] found that Phx-3 exerted a strong proapoptotic effect on neutrophils in
human blood and almost completely suppressed the generation of superoxide (O2−) from human
neutrophils. Kohno et al. [31] also indicated that Phx-3 has the ability to suppress inflammation, because
Phx-3 inhibited the activity of cyclooxygenase-1 (Cox-1) and Cox-2, that of nitric oxide synthetase, and
the production of interleukin 6 in macrophages, which are significantly involved in inflammation. Thus,
we assumed that the anticancer activity of Phx-3 may be exerted through the suppression of superoxide
Int. J. Mol. Sci. 2013, 14
17575
generation and reduction in the number of neutrophils in the peripheral blood in patients with colon
cancer, which may be designated as an indirect anticancer activity of Phx-3 for preventing
carcinogenesis of colon cancer.
Moreover, H. pylori is a major factor in the carcinogenesis of gastric cancer including gastric
lymphoma and adenocarcinoma, and abolishing these bacteria from the stomach may reduce the
incidence of the gastric cancer [32,33]. Hanawa et al. [11] found that Phx-3 efficiently kills H. pylori,
in vitro, which should be regarded as an indirect anticancer activity of Phx-3 on gastric cancer
carcinogenesis. These indirect anticancer effects of Phx-3 were analyzed in terms of preventing
carcinogenesis of gastric and colon cancers.
2. Direct Anticancer Activity of Phx-3 on Gastric and Colon Cancers
Gastric cancer and colon cancer, mostly adenocarcinoma, are refractory to chemotherapy alone [34,35].
Gastric cancer is a common malignancy in Japanese adults and has recently increased in Western
adults [34,36]. Colon cancer is a major public health problem worldwide, and its incidence is increasing
annually [35,37]. In spite of tremendous efforts to prevent the development of gastric and colon cancers,
the anticancer drugs to abolish these malignancies are not still developed; thus, surgical therapy is a
first-line treatment of these types of cancer. Since we found that Phx-3 extensively prevents the growth
of gastric and colon cancer cell lines in vitro [8,15–17], we analyzed its cytotoxic and proapoptotic
activities, focusing on the anticancer mechanism for preventing the development of gastric and
colon cancer.
2.1. Cytotoxic and Proapoptotic Effects of Phx-3 on Gastric and Colon Cancer Cells in Vitro
Kasuga et al. [15] examined the anticancer activity of Phx-3 on human gastric cancer cell lines,
MKN45, MKN74, MKN7 and KATO III cells in vitro, and demonstrated that Phx-3 caused cytotoxic
(50% inhibition of cell growth, IC50: less than 10 μM) and proapoptotic effects on these cells at lower
concentrations. These cytotoxic effects of Phx-3 were stronger than those of 5-fluorouracil that is
clinically administered to patients with the advanced gastric cancer, taking into account the results of
Osaki et al. [38] that 1 mM 5-fluorouracil induced variable degrees of apoptosis in the cultured gastric
cancer cell lines (14% in MKN74, 12% in MKN45, 3% in MKN28 and 0.5% in KATO-III), and 50 μM
5-fluorouracil had little effect on the induction of apoptosis in these gastric cancer cell lines. In addition,
Nakachi et al. [17] studied the anticancer activity of Phx-3 on human colon cancer cell lines, COLO20,
DLDl and PMCO1 cells, and demonstrated that it caused cytotoxic (IC50: less than 10 μM) and
proapoptotic effects on these cells. Cell growth was extensively inhibited by Phx-3 in another colon
cancer cell line, Lovo-1 (IC50: 20 μM), as well [8]. These results indicate that Phx-3 exhibits strong
anticancer activity against gastric and colon cancer cells, in vitro. Phx-3 did not affect the growth of the
normal cell line—human umbilical vein endothelial cells (HUVECs)—at concentrations less than
60 μM [39], suggesting that Phx-3 may exert a less adverse effect on normal cells.
Int. J. Mol. Sci. 2013, 14
17576
2.2. Phx-3 Induces the Apoptotic Cell Death of Gastric and Colon Cancer Cells by Reducing the
Higher pHi of These Cells
Extracellular pH (pHe) is usually higher than pHi in normal cells, as explained by Donnan’s classical
membrane equilibrium theory. However, this view does not necessarily explain the extremely acidic pH
in the outer interstitial medium of tumor tissues [40–42]. Therefore, it has been assumed that some
mechanism to discharge the hydrogen ion from the cytosol to the extracellular medium might operate in
cancer cells. Recent findings indicate that Na+/H+ exchanger isoform 1 (NHE1), which is ubiquitously
present in the plasma membrane in normal and cancerous cells, plays a pivotal role in regulating pHi in
cancer cells by discharging the cytosolic hydrogen ion to the outside [43–45]. Actually, pHi is more
alkaline in cancer cells than in normal cells. Reshkin et al. [46] reported that pHi is far higher in cancer
cells (7.12–7.7) than in normal cells (6.99–7.05). Che et al. [8,47] demonstrated that pHi in more than 10
species of cancer cell lines originating from different organs exceeded 7.4 (pHi in the extreme case was 7.7).
Nagata et al. [16] found that pHi in the human gastric cancer cell lines MKN45 and MKN74 exceeds
pHe (pHi of 7.48 for MKN45 and 7.5 for MKN74 cells, versus medium pH of 7.4). Colon cancer cell
line, Lovo-1 cells, exhibited higher pHi (pHi = 7.61) [7]. Higher pHi in cancer cells seems to be suitable
for proliferation and oncogene transformation of the cells [48,49], and increases tumorigenesis [48–51].
Therefore, agents to reduce pHi in cancer cells might be promising anticancer drugs, as has been
predicted by several researchers [40,46,50]. Nagata et al. [16] demonstrated that when human gastric
cancer cells (including MKN45 and MKN74 cells) were treated with Phx-3, pHi decreased rapidly,
dependent on the dose of Phx-3, and such intracellular acidification was sustained for at least 4h. In
particular, pHi decreased by 1.6pH units in MKN45 cells and 1.2pH units in MKN74 cells immediately
after administration of 100 μM Phx-3. Such rapid and drastic changes in pHi in these gastric cancer cells
could be explained by the inhibition of NHE1 caused by administering Phx-3. A close relationship
between anticancer activity of Phx-3 on these gastric cell lines and a decreased extent of pHi caused by
Phx-3 was shown [16]. It also confirmed a causal relationship between ΔpHi and cytotoxic effects due to
Phx-3 in various cancer cell lines [8].
An extensive pHi decrease may promote proapoptotic signaling in gastric and colon cancer cells.
Specifically, the decrease of pHi activates caspase-3, an important executor of apoptosis, and DNase II,
a pH-dependent endonuclease that is responsible for DNA fragmentation, thus inducing apoptotic cell
death of these cancer cells [52,53]. This view is consistent with a report by Perez-Sala et al. [54] that
when HL-60 cells (a human leukemia cell line) were treated with either ionomycin or lovastatin, cellular
apoptosis was induced as a result of intracellular acidification and activation of DNase II.
The mechanism by which Phx-3 inhibits NHE1 may be explained by the findings of Hendrich et al. [55]
that phenoxazine molecules are located close to the polar/apolar interface of lipid bilayers and weakly
interact with lipid bilayers, altering the lipid phase properties of the cellular membranes. It is possible
that rapid changes in the conditions of the plasma membranes induced by Phx-3 significantly affect the
activity of NHE1 in the cellular membranes. It is noteworthy that the action of Phx-3 seems to be
opposite to that of 12-O-tetradecanoylphorbol-13-acetate (TPA), a strong cancer promoter that interacts
with phospholipid bilayers to increase pHi. This view is consistent with the findings of Azuine et al. [56]
that the cancer promotion action of TPA was cancelled by the phenoxazine compounds.
Int. J. Mol. Sci. 2013, 14
17577
2.3. Dysfunction of the Mitochondria in Gastric and Colon Cancer Cells by Phx-3
Depolarization of mitochondria is an eminent change that activates caspases and greatly influences
the apoptotic events in cancer cells [52,53]. In gastric and colon cancer cells, treatment with Phx-3
significantly depolarizes mitochondria, followed by apoptotic cell death of these cancer cells [8,16].
This result is consistent with recent reports [6,8] that Phx-3 depolarizes mitochondria in a variety of
cancer cell lines originating from different organs. Therefore, Phx-3 may exert strong anticancer activity
on gastric and colon cancers via depolarization of mitochondria in these cells.
2.4. Plausible Mechanism for the Anticancer Effects of Phx-3 on Gastric and Colon Cancer Cells
The proapoptotic activity of Phx-3 may be explained by the mechanism depicted in Scheme 1. First,
Phx-3 may inhibit the activity of NHE1 and cause a drastic reduction of pHi in gastric and colon cancer
cells, which activates caspase-3 and DNase II that are responsible for apoptotic cell death signaling in
these cells.
Scheme 1. Plausible mechanism for anticancer effects of Phx-3 on gastric and colon cancer cells.
Serine/threonine kinase Akt mediates a variety of survival signaling, participating in the growth
factor maintenance of cell survival and preventing cancer cells from becoming apoptotic. Therefore, it is
important to suppress Akt signaling to prevent the survival of cancer cells, and agents to inhibit activity
of Akt may be promising for cancer chemotherapy. Enoki et al. [57] initially reported the significant
activity of Phx-1 (2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one), another oxidative
phenoxazine, in suppressing the phosphorylation of Akt in rat basophilic leukemia RBL-2H3 cells.
Hara et al. [58] demonstrated that Phx-1 inhibits the proliferation and serum-induced phosphorylation of
Akt in Jurkat cells, a human T cell leukemic cell line. Thimmaiah et al. [59] examined in detail the effect
of various synthetic phenoxazines and demonstrated that N10-substituted phenoxazines such as
10-[4'-(N-diethylamino) butyl]-2-chlorophenoxazine and 10-[4'((beta-hydroxyethyl)piperazineo)butyo]-2-chlorophenoxazine strongly inhibited Akt phosphorylation. Zheng et al. [7] demonstrated that
Phx-3 inhibited the phosphorylation of Akt in human lung adenocarcinoma cell line A549 cells,
suggesting that Phx-3 strongly suppresses Akt signaling in cancer cells, though it is not clear whether
Int. J. Mol. Sci. 2013, 14
17578
Phx-3 inhibits Akt signaling in gastric and colon cancer cells, therefore being still hypothetical. Based on
these results, Scheme 1 summarizes the plausible mechanism for Phx-3 inducing apoptosis in cancer cells.
3. Indirect Anticancer Activity of Phx-3 on Gastric and Colon Cancers
H. pylori infection is associated with gastric lymphomas and adenocarcinomas, and now is
designated as class I carcinogens [32,33]. Therefore, eliminating these bacteria would prevent
carcinogenesis of gastric cancer. Hanawa et al. [11] reported that H. pylori is sensitive to Phx-3
treatment at a lower concentration of 2 μM, suggesting that Phx-3 may contribute to preventing
carcinogenesis of gastric cancer by killing these bacteria. Overexpression of Cox-2 increases the
proliferation of gastric cancer cell lines, and inhibiting Cox-2 slows the growth of stomach cancer
xenografts in nude mice [60]. Kohno et al. [31] demonstrated that Phx-3 inhibits Cox-2 in macrophages.
Thus, Phx-3 may slow the growth of stomach cancer.
Neutrophils have recently attracted much attention in terms of carcinogenesis, metastasis and
angiogenesis of cancers. According to a recent review by Gregori and Houghton [21], neutrophils
influence inflammatory cell recruitment and activation by producing cytokines and chemokines, and
regulate tumor cell proliferation, angiogenesis, and metastasis by secreting reactive oxygen species
(ROS) and proteases. Thus, the manipulating neutrophils may be useful for treating cancers. In 1995,
Tabuchi et al. [23] first indicated that neutrophils play a critical role in the development of colon cancer,
because using granulocyte apheresis to remove these cells from the blood of patients with colon cancer
extensively reduced the cancer size. Shimazaki et al. [61] also indicated that the G/L ratio is clinically
relevant biomarker of long-term cancer progression in patients with colorectal cancer. Therefore, drugs
that selectively decrease the number of circulating neutrophils in the blood may be beneficial for treating
colon cancer. The recent discovery of Tabuchi et al. [30] that when freshly obtained blood was treated
with 50 μM Phx-3 at 37 °C for 18 h, the population of apoptotic neutrophils increased to more than 50%,
but no apoptotic lymphocytes were seen, may be of significance in treating colon cancer. This would be
designated as an indirect anticancer effect of Phx-3 on colon cancer.
Neutrophils seem to be involved in ulcerative colitis, which is associated with the carcinogenesis
of colon cancer [28,29]. Neutrophils, which produce a large amount of active oxygen during
inflammation [62,63], may be associated with the onset of ulcerative colitis [28,29], therefore,
suppression of neutrophil activity may lead to preventing ulcerative colitis, and finally to preventing the
carcinogenesis of colon cancer. Phx-3 may be a promising drug for treating ulcerative colitis because it
almost completely suppressed generation of superoxide (O2−) from human neutrophils in vitro [30].
Such indirect anticancer effects of Phx-3 on carcinogenesis of colon cancer should be confirmed by
further experiments using animals.
4. Future Aspect of Phx-3 as Anticancer Drug for the Treatment of Gastric and Colon Cancers
In this review, we surveyed the direct and indirect anticancer activity of Phx-3 on gastric and colon
cancer; however, these findings should be confirmed in experiments using animals. Though we did not
apply Phx-3 to mice with gastric or colon cancer, we found that Phx-3 extensively suppressed the
development and metastasis of malignant melanoma cells transplanted in mice [9,10]. The results of the
panel test conducted by Miyake et al. [64] may suggest the availability of Phx-3 to humans, because they
Int. J. Mol. Sci. 2013, 14
17579
demonstrated that when the patients with gastritis were administered with the tablet (200 mg) containing
1 μg Phx-3 after each dinner for one week, their gastric conditions were much improved, as evaluated
based on the patients’ conditions of the stomach, in comparison with the control patients without
administration of the tablet. Also, Phx-3 had few adverse effects on mice at higher doses [9,10].
Kohno et al. [31] reported that oral administration of 500–1500 mg/kg Phx-3 to ddY mice did not cause
gastrointestinal injury and that repeated oral administration of 10 mg/kg Phx-3 to mice for four weeks
caused no diarrhea. Therefore, it would be significant to investigate whether or not Phx-3 holds promise
as an agent to treat human gastric and colon cancer.
Acknowledgments
The present research was supported in part by funds from the Private University Strategic
Research-Based Support Project (Molecular Information-based Intractable Disease Research Project)
from the Ministry of Education, Culture, Sports, Science and Technology of Japan (2008-2012).
Conflicts of Interest
The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
Anzai, K.; Isono, K.; Okuma, K.; Suzuki, S. The new antibiotics, questiomycins A and B.
J. Antibiotics 1960, 13, 125–132.
Tomoda, A.; Yamaguchi, J.; Kojima, H.; Amemiya, H.; Yoneyama, Y. Mechanism of
o-aminophenol metabolism in human erythrocytes. FEBS Lett. 1986, 196, 44–48.
Shimizu, S.; Suzuki, M.; Miyazawa, K.; Yokoyama, T.; Ohyashiki, K.; Miyazaki, K.; Abe, A.;
Tomoda, A. Differentiation and apoptosis in human malignant melanoma G-361 cells induced by
2-aminophenoxazine-3-one. Oncol. Rep. 2005, 14, 41–46.
Kato, S.; Shirato, K.; Imaizumi, K.; Toyota, H.; Mizuguchi, J.; Odawara, M.; Che, X-F.; Akiyama, S.;
Abe, A.; Tomoda, A. Anticancer effects of phenoxazine derivatives combined with tumor necrosis
factor-related apoptosis-inducing ligand on pancreatic cancer cell lines, KLM-1 and MIA-PaCa-2.
Oncol. Rep. 2006, 15, 843–848.
Shirato, K.; Imaizumi, K.; Miyazawa, K.; Takasaki, A.; Mizuguchi, J.; Che, XF.; Akiyama, S.;
Tomoda, A. Apoptosis induction preceded by mitochondrial depolarization in multiple myeloma
cell line U266 by 2-aminophenoxazine-3-one. Biol. Pharm. Bull. 2008, 31, 62–67.
Takasaki, A.; Hanyu, H.; Iwamoto, T.; Shirato, K.; Izumi, R.; Toyota, H.; Mizuguchi, J.; Miyazawa, K.;
Tomoda, A. Mitochondrial depolarization and apoptosis associated with sustained activation of
c-jun-N-terminal kinase in the human multiple myeloma cell line U266 induced by
2-aminophenoxazine-3-one. Mol. Med. Rep. 2009, 2, 199–203.
Zheng, C.L.; Che, X.-F.; Akiyama, S.; Miyazawa, K.; Tomoda, A. 2-Aminophenoxazine-3-one
induces cellular apoptosis by causing rapid intracellular acidification and generating reactive
oxygen species in human lung adenocarcinoma cells. Int. J. Oncol. 2010, 36, 641–650.
Int. J. Mol. Sci. 2013, 14
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
17580
Che, X.F.; Zheng, C.L.; Akiyama, S.; Tomoda, A. 2-Aminophenoxazine-3-one and 2-amino4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher
intracellular pH in cancer cells. Proc. Jpn. Acad. Ser. B 2011, 87, 199–213.
Miyano-Kurosaki, N.; Kurosaki, K.; Hayashi, M.; Takaku, H.; Hayafune, M.; Shirato, K.; Kasuga, T.;
Endo, T.; Tomoda, A. 2-Aminophenoxazine-3-one suppresses the growth of mouse malignant
melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol. Pharm. Bull. 2006, 29, 2197–2201.
Hongo, T.; Miyano-Kurosaki, N.; Kurosaki, K.; Hata, A.; Tomoda, A. 2-Aminophenoxazine-3-one
prevents pulmonary metastasis of mouse B16 melanoma cells in mice. J. Pharmacol. Sci. 2010,
114, 63–68.
Hanawa, T.; Osaki, T.; Manzoku, T.; Fukuda, M.; Kawakami, H.; Tomoda, A.; Kamiya, S. In vitro
antibacterial activity of Phx-3 against Helicobacter pylori. Biol. Pharm. Bull. 2010, 33, 188–191.
Uruma, T.; Yamaguchi, H.; Fukuda, M.; Kawakami, H.; Goto, H.; Kishimoto, T.; Yamamoto, Y.;
Tomoda, A.; Kamiya, S. Chlamydia pneumoniae growth inhibition in human monocytic THP-1
cells and human epithelial HEp-2 cells by a novel phenoxazine derivative. J. Med. Microbiol. 2005,
54, 1143–1149.
Shimizu, S.; Suzuki, M.; Tomoda, A.; Arai, S.; Taguchi, H.; Hanawa, T.; Kamiya, S. Phenoxazine
compounds produced by the reactions with bovine hemoglobin show antimicrobial activity against
non-tuberculosis mycobacteria. Tohoku J. Exp. Med. 2004, 203, 47–52.
Hayashi, K.; Hayashi, T.; Tomoda, A. Phenoxazine derivatives inactivate human cytomegalovirus,
herpes simplex virus-1, and herpes simplex virus-2 in vitro. J. Pharmacol. Sci. 2008, 106, 369–375.
Kasuga, T.; Tabuchi, T.; Shirato, K.; Imaizumi, K.; Tomoda, A. Caspase-independent cell death
revealed in human gastric cancer cell lines, MKN45 and KATO III treated with phenoxazine
derivatives. Oncol. Rep. 2007, 17, 400–415.
Nagata, H.; Che, X.-F.; Miyazawa, K.; Tomoda, A.; Konishi, M.; Ubukata, H.; Tabuchi, T. Rapid
decrease of intracellular pH associated with inhibition of Na+/H+ exchanger precedes apoptotic events
in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one.
Oncol. Rep. 2011, 25, 341–346.
Nakachi, T.; Tabuchi, T.; Takasaki, A.; Arai, S.; Miyazawa, K.; Tomoda, A. Anticancer activity of
phenoxazines produced by bovine erythrocytes on colon cancer cells. Oncol. Rep. 2010, 23,
1517–1522.
Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 37,
539–545.
Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 430, 860–867.
Richards, C.H.; Roxburgh, C.S.; Anderson, J.H.; McKee, R.F.; Foulis, A.K.; Horgan, P.G.;
McMillan, D.C. Prognostic value of tumour necrosis and host inflammatory responses in colorectal
cancer. Br. J. Surg. 2012, 99, 287–294.
Gregori, A.; Houghton, A. Tumor-associated neutrophils: New targets for cancer therapy.
Cancer Res. 2011, 71, 2411–2416.
Tabuchi, T.; Soma, T.; Yonekawa, M.; Komai, T.; Hashimoto, T.; Adachi, M. Reduction of VX2
transplanted tumor by granulocyte depletion using extracorporeal circulation on rabbit models.
Anticancer Res. 1992, 12, 795–798.
Int. J. Mol. Sci. 2013, 14
17581
23. Tabuchi, T.; Ubukata, H.; Sato, S.; Nakata, I.; Goto, Y.; Watanabe, Y.; Hashimoto, T.; Mizuta, T.;
Adachi, M.; Soda, T. Granulocytapheresis as a possible cancer treatment. Anticancer Res. 1995, 15,
985–990.
24. Tabuchi, T.; Ubukata, H.; Saniabadi, A.; Soma, T. Granulocyte apheresis as a possible new
approach in cancer therapy: A pilot study involving two cases. Cancer Detect. Prev. 1999, 23,
417–421.
25. Satomi, A.; Murakami, S.; Ishida, K.; Matsuri, M.; Hashimoto, T.; Sonoda, M. Significance of
increased neutrophils in patients with advance colorectal cancer. Acta Oncol. 1995, 34, 69–73.
26. Chua, W.; Charles, K.A.; Baracos, V.E.; Clarke, S.J. Neutrophil/lymphocyte ratio predicts
chemotherapy outcomes in patients with advanced colorectal cancer. Brit. J. Cancer 2011, 104,
1288–1295.
27. Rao, H.L.; Chem, J.W.; Fu, X.J.; Zeng, Y.X.; Cai, M.Y.; Xie, D. Increased intratumoral neutrophil
in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse
prognosis. PLoS One 2012, 7, e30806.
28. Stratton, J.; Swanson, P.E.; Upton, M.P. Ulcerative colitis pathology. Available online:
http://emedicine.medscape.com/article/2005396-overview (accessed on 26 May 2011).
29. Shang, K.; Bai, U.P.; Wang, C.; Wang, Z.; Yu, H.; Du, X.; Zhou, X.Y.; Chi, Y.U.; Mukaida, N.;
Li, Y.Y. Crucial involvement of tumor-associated neutrophils in the regulation of chronic
colitis-associated carcinogenesis in mice. PLoS One 2012, 7, e51848.
30. Tabuchi, T.; Che, X.F.; Hiraishi, K.; Adachi, M.; Miyano, K.; Sumimoto, H.; Tabuchi, T.;
Miyazawa, K.; Tomoda, A. Selectively induced apoptosis in human neutrophils in the presence
of oxidative phenoxazines, 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one and
2-aminophenoxazine-3-one, preceded by decrease of intracellular pH, depolarization of the
mitochondria, and inhibition of superoxide generation. J. Pharmacol. Sci. 2011, 117, 139–148.
31. Kohno, K.; Miyake, M.; Sano, O.; Tanaka-Kataoka, M.; Yamamoto, S.; Koya-Miyata, S.; Arai, N.;
Fujii, M.; Watanabe, H.; Ushio, S.; et al. Anti-inflammatory and immunomodulatory properties of
2-amino-3-phenoxazine-3-one. Biol. Pharm. Bull. 2008, 31, 1938–1943.
32. Bonin, S.; Schwarz, R.E.; Blanke, C.D. Gastric Cancer. In Cancer Management: A
Multidisciplinary Approach; Pazdru, R., Coia, L.R., Hoskins, W., Wagman, L.D., Eds.; PPR Inc.:
Melville, NY, USA, 2002; pp. 235–247.
33. Sepulveda, A.R. Helicobacter, inflammation, and gastric cancer. Curr. Pathobiol. Rep. 2013, 1,
9–18.
34. Crew, K.N.; Neugut, A.L. Epidemiology of gastric cancer. World J. Gastroenterol. 2006, 12,
354–362.
35. Saliz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbachr, L.; Moore, M.J.; Maroun, J.A.;
Ackland, S.P.; Locker, P.K.; Pirotta, N.; et al. Irinotecan plus fluorouracil and leucovorin for
metastatic colorectal cancer. N. Engl. J. Med. 2000, 343, 905–914.
36. Smith, M.G.; Hold, G.L.; Tahara, E.; El-Omar, E.M. Cellular and molecular aspects of gastric
cancer. World J. Gastroenterol. 2006, 12, 2979–2990.
37. Dulabh, K.; Monga, M.D.; O’Connell, M.J. Surgical adjuvant therapy for colorectal cancer: Current
approaches and future directions. Anal. Surg. Oncol. 2006, 13, 1021–1034.
Int. J. Mol. Sci. 2013, 14
17582
38. Osaki, M.; Tanabe, S.; Goto, A.; Hayashi, H.; Oshimura, M.; Ito, H. 5-Fluorouracil (5-FU) induced
apoptosis in gastric cancer cell lines: Role of the p53 gene. Apoptosis 1997, 2, 221–226.
39. Fukuda, G.; Yoshitake, N.; Khan, Z.A.; Kanazawa, M.; Notoya, Y.; Che, X.F.; Akiyama, S.;
Tomoda, A.; Chakrabarti, S.; Odawara, M. 2-Aminophenoxazine-3-one attenuates glucose-induced
augmentation of embryonic form of myosin heavy chain, endothelin-l and plasminogen activator
inhibitor-1 in human umbilical vein endothelial cells. Biol. Pharm. Bull. 2005, 28, 797–801.
40. Izumi, H.; Torigoe, T.; Ishiguchi, H.; Urano, H.; Yoshida, Y.; Tanabe, M.; Ise, T.; Murakami, T.;
Yoshida, T.; Nomoto, M.; et al. Cellular pH regulators: Potentially promising molecular targets for
cancer therapy. Cancer Treat. Rev. 2003, 29, 541–549.
41. Yamagata, M.; Tannock, I.F. The chronic administration of drugs that inhibit the regulation of
intracellular pH in vitro and anti-tumor effects. Brit. J. Cancer 1996, 73, 1328–1334.
42. Wahl, M.L.; Owen, J.A.; Burd, R.; Herlands, R.A.; Nogami, S.S.; Rodeck, U.; Beerd, D.;
Leeper, D.B.; Owen, C.S. Regulation of intracellular pH in human melanoma: Potential therapeutic
implications. Mol. Cancer Ther. 2002, 1, 617–628.
43. Tse, C.M.; Levine, S.A.; Yun, C.H.C.; Brant, S.R.; Nath, S.; Pouyssegur, J.; Donowitz, M. Molecular
properties, kinetics and regulation of mammalian Na+/H+ exchangers. Cell. Physiol. Biochem.
1994, 4, 282–300.
44. Putney, L.K.; Denker, S.P.; Barber, D.L. The changing face of the Na+/H+ exchanger, NHE1:
Structure, regulation, and cellular actions. Ann. Rev. Pharmacol. Toxicol. 2002, 42, 527–552.
45. Rich, I.N.; Worthington-White, D.; Garden, O.A.; Musk, P. Apopotosis of leukemic cells
accompanies reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger. Blood
2000, 95, 1427–1434.
46. Reshkin, S.J.; Cardone, R.; Harguindey, S. Na+-H+ exchanger, pH regulation and cancer.
Recent Pat. Anti-Cancer Drug Discovery 2013, 8, 85–99.
47. Che, X.F.; Akiyama, S.; Tomoda, A. Suppression of the proliferation of cancer cell lines, KB-3-1
and K562 cells preceded by a decrease in intracellular pH caused by phenoxazine derivative.
Oncol. Rep. 2008, 19, 1253–1258.
48. Lagadic-Gossmann, D.; Huc, L.; Lecureur, V. Alteration of intracellular pH homeostasis in
apoptosis: Origin and roles. Cell Death Differ. 2004, 11, 953–961.
49. Shrode, L.D.; Tapper, H.; Grinstein S. Role of intracellular pH in proliferation, transformation and
apoptosis. J. Bioenerg. Biomembr. 1979, 29, 293–299.
50. Harguindey, S.; Orive, G.; Pedraz, J.L.; Paradioso, A.; Reshkins, S.J. The role of pH dynamics and
the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same
coin—One single nature. BBA-Rev. Cancer 2005, 1756, 1–24.
51. Harguindey, S.; Arranz, H.; Wahl, M.L.; Orive, G.; Reshkin, S.J. Proton transport inhibitors as
potentially selective anticancer drugs. Anticancer Res. 2009, 29, 2127–2136.
52. Matsuyama, S.; Reed, J. Mitochondria dependent apoptosis and cellular pH regulation.
Cell Death Differ. 2000, 7, 1155–1165.
53. Matsuyama, S.; Liopis, J.; Deveraux, Q.L.; Tsien, R.Y.; Reed, J.C. Changes in intramitochondrial
and cytosolic pH homeostasis in apoptosis: Early events that modulate caspase activation during
apoptosis. Nat. Cell Biol. 2000, 2, 315–325.
Int. J. Mol. Sci. 2013, 14
17583
54. Perez-Sala, D.; Collado-Escobar, D.; Mollinedo, F. Intracellular alkalinization suppresses
lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent
endonuclease. J. Biol. Chem. 1995, 270, 6235–6242.
55. Hendrich, A.B.; Stanczak, K.; Komorowska, M.; Motohashi, N.; Kawase, M.; Kichalak, K. A study
on the perturbation of model lipid membranes by phenoxazines. Bioorg. Med. Chem. 2006, 14,
5948–5954.
56. Azuine, M.A.; Tokuda, H.; Takayasu, J.; Enjyo, F.; Mukainaka, T.; Konoshima, T.; Nishino, H.;
Kapadia, G.J. Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic
analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen
activation and the mouse skin two-stage carcinogenesis models. Pharmacol. Res. 2004, 49,
161–169.
57. Enoki, E.; Sada, K.; Qu, X.; Kyo, S.; Miah, S.M.S.; Hatani, T.; Tomoda, A.; Yamamura, H. The
phenoxazine derivative Phx-1 suppresses IgE-mediated degranulation in rat basophilic leukemia
RBL-2H3 cells. J. Pharm. Sci. 2004, 94, 329–333.
58. Hara, K.; Okamoto, M.; Aki, T.; Yagita, H.; Tanaka, H.; Mizukami, Y.; Nakamura, H.; Tomoda, A.;
Hamasaki, N.; Kang, D. Synergistic enhancement of TRAIL- and tumor necrosis factor α-induced
cell death by a phenoxazine derivative. Mol. Cancer Ther. 2005, 4, 1121–1127.
59. Thimmaiah, K.N.; Easton, J.B.; Germain, G.S.; Morton, C.L.; Kamath, S.; Buolamwinini, J.K.;
Houghton, P.J. Identification of N10 substituted phenoxazines as potential and specific inhibitors of
Akt signaling. J. Biol. Chem. 2005, 280, 31924–31935.
60. Fan, X.M.; Jiang, X.H.; Gu, G.; Ching, Y.P.; He, H.; Xia, H.H.X.; Lin, M.C.M.; Chan, A.O.O.;
Yen, M.F.; Kung, H.F.; et al. Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in
gastric cancer cells. Digestion 2006, 73, 75–82.
61. Shimazaki, J.; Goo, Y.; Nishida, K.; Tabuchi, T.; Motohashi, G.; Ubukata, H.; Tabuchi, T. In patients
with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are
clinically relevant biomarkers of long-term cancer progression. Oncology 2013, 84, 356–361.
62. Rossi, F. The O2−-forming NADPH oxidase of the phagocytes: Nature, mechanism of activation
and function. Biochim. Biophys. Acta 1986, 833, 65–69.
63. Cross, A.R.; Jones, O.T.G. Enzymic mechanisms of superoxide production. Biochim. Biophys. Acta
1991, 1057, 281–298.
64. Miyake, M.; Kohno, K.; Sano, O. Antiinflammatory agent comprising 2-aminophenol or derivative
thereof as active ingredient. Eur. Patents Appl. WO 2008/047758, 24 April 2008.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).